Johnson & Johnson $JNJ Holdings Lowered by InvesTrust

InvesTrust lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 13.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,394 shares of the company’s stock after selling 2,327 shares during the quarter. Johnson & Johnson makes up about 1.5% of InvesTrust’s investment portfolio, making the stock its 22nd largest holding. InvesTrust’s holdings in Johnson & Johnson were worth $4,075,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. National Pension Service lifted its stake in Johnson & Johnson by 1.3% during the second quarter. National Pension Service now owns 5,226,968 shares of the company’s stock worth $1,327,493,000 after purchasing an additional 67,484 shares during the last quarter. IFP Advisors Inc increased its stake in Johnson & Johnson by 8.8% during the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after purchasing an additional 3,133 shares during the last quarter. Elefante Mark B increased its stake in Johnson & Johnson by 9.8% during the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock valued at $7,285,000 after purchasing an additional 2,563 shares during the last quarter. Signal Advisors Wealth LLC increased its stake in Johnson & Johnson by 76.1% during the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock valued at $3,697,000 after purchasing an additional 6,539 shares during the last quarter. Finally, Gradient Investments LLC raised its holdings in shares of Johnson & Johnson by 9.9% during the second quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock worth $38,815,000 after purchasing an additional 13,737 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.1%

NYSE:JNJ opened at $253.68 on Friday. The firm has a market capitalization of $611.35 billion, a P/E ratio of 38.44, a P/E/G ratio of 2.59 and a beta of 0.21. The business has a 50 day simple moving average of $265.73 and a 200 day simple moving average of $249.57. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. Johnson & Johnson has a 12-month low of $184.66 and a 12-month high of $281.07.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period last year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts predict that Johnson & Johnson will post 11.10 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported third-quarter adjusted earnings of $2.59 per share and revenue of $25.40 billion, exceeding consensus estimates. Revenue increased 5.9% year over year, led by 7.9% growth in Innovative Medicine. J&J Q3 2026 Earnings Call Transcript
• Positive Sentiment: Management raised its 2026 sales and earnings outlook, with guidance of approximately $11.05–$11.15 in adjusted EPS. Executives also highlighted pipeline products and MedTech innovation as potential sources of future growth. JNJ Q3 Earnings Call Highlights
• Positive Sentiment: Morgan Stanley maintained an “overweight” rating, while RBC retained an “outperform” rating, indicating that analysts still see potential upside despite trimming their price targets. Technical analysts also identified support near $246. Morgan Stanley JNJ Price Target
• Neutral Sentiment: Johnson & Johnson plans an enterprise review on December 8 and is targeting a potential mid-2027 spinoff of its DePuy Synthes orthopedics business. These initiatives could clarify the company’s growth strategy but may also create execution and earnings-dilution concerns. J&J MedTech Orthopedics Spinoff
• Negative Sentiment: MedTech sales missed Wall Street expectations, with weakness attributed partly to China pricing pressure and European budget cuts. Investors viewed the device business as a key reason the stock fell sharply following earnings. Johnson & Johnson Stock Falls as MedTech Misses
• Negative Sentiment: Analysts lowered several price targets after the results, citing mixed pharmaceutical trends, acquisition costs, talc-related charges and potential 2027 dilution. The concerns are more significant because JNJ trades at a premium earnings multiple versus the broader market. Analysts Cut JNJ Forecasts

Analyst Ratings Changes

A number of research analysts have recently issued reports on JNJ shares. Royal Bank Of Canada reduced their price target on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a research report on Wednesday. Leerink Partners lowered their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research report on Wednesday. Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Sanford C. Bernstein set a $270.00 target price on shares of Johnson & Johnson in a report on Thursday. Finally, JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $274.35.

Insider Activity

In related news, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 87,569 shares of company stock worth $23,064,544 over the last ninety days. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.